<body><a name="drugname"></a><table class="topbox" width="100%">
<tr>
<td><span class="topboxgenname">BOTULINUM TOXIN TYPE A</span><br/>(bo'tul-i-num)<br/><span class="topboxtradename">Botox, </span><span class="topboxtradename">BOTOX Cosmetic<br/></span><b>Classifications:</b> <span class="classification">autonomic nervous system agent</span>; <span class="classification">skeletal muscle relaxant</span>; <span class="classification">antispasmodic</span><br/><b>Pregnancy Category: </b>C<br/></td>
</tr>
</table>
<h1><a name="avail">Availability</a></h1>
<p>100 units powder for injection</p>
<h1><a name="action">Actions</a></h1>
<p>Botulinum toxin type A blocks neuromuscular transmission by binding to receptor sites on motor nerve terminals, entering the
         nerve terminals, and inhibiting the release of acetylcholine. This inhibition occurs as the neurotoxin splits a protein molecule
         integral to the successful docking and releasing of acetylcholine from storage areas located within nerve endings.
      </p>
<h1><a name="therapef">Therapeutic Effects</a></h1>
<p>When injected intramuscularly at therapeutic doses, botulinum toxin type A produces partial chemical denervation of the muscle
         resulting in a localized reduction in muscle activity.
      </p>
<h1><a name="uses">Uses</a></h1>
<p>Treatment of blepharospasm, cervical dystonia, strabismus, glabellar frown wrinkles, severe axillary hyperhidrosis.</p>
<h1><a name="unlabeleduses">Unlabeled Uses</a></h1>
<p>Treatment of other types of wrinkles, migraine headache, achalasia, focal spasticity associated with cerebral palsy with concurrent
         equinus gait, spasticity associated with stroke.
      </p>
<h1><a name="contrain">Contraindications</a></h1>
<p>Presence of infection at the proposed injection site(s); hypersensitivity to Botox. Patients with dysphagia or respiratory
         compromise; pregnancy (category C); lactation.
      </p>
<h1><a name="precaution">Cautious Use</a></h1>
<p>In individuals with peripheral motor neuropathic diseases (e.g., amyotrophic lateral sclerosis, or motor neuropathy), or neuromuscular
         junctional disorders (e.g., myasthenia gravis or Lambert-Eaton syndrome); neuromuscular disorders; cardiovascular disease;
         inflammation at the proposed injection site; weakness in the target muscle(s).
      </p>
<h1><a name="rtedsg">Route &amp; Dosage</a></h1>
<table cellpadding="4" cellspacing="0" class="rdbox" width="100%">
<tr>
<td><span class="indicationtitle">Blepharospasm</span><br/><span class="rdage">Adult/Child:</span> <span class="rdroute">Intradermal</span>
<i>&gt;12 y</i> 1.252.5 U injected at each site,  may repeat in 3 mo if needed; cumulative dose should not exceed 200 U in a 30-d period<br/><br/><span class="indicationtitle">Cervical Dystonia</span><br/><span class="rdage">Adult/Adolescent:</span> <span class="rdroute">IM</span>
<i>&gt;16 y</i> 198300 U divided among affected muscles <br/><br/><span class="indicationtitle">Frown Wrinkles</span><br/><span class="rdage">Adult:</span> <span class="rdroute">IM</span> 25 U divided among affected muscles in 5 step doses, may repeat in 34 mo if needed<br/><br/><span class="indicationtitle">Other Wrinkles</span><br/><span class="rdage">Adult:</span> <span class="rdroute">SC</span> 12 U per site<br/><br/><span class="indicationtitle">Spasticity</span><br/><span class="rdage">Adult:</span> <span class="rdroute">IM</span> 2050 U per affected site<br/><span class="rdage">Child:</span> <span class="rdroute">IM</span>
<i>218 y</i> 4 U/kg (max: 200 U per treatment) every 3 mo<br/><br/><span class="indicationtitle">Axillary Hyperhydrosis</span><br/><span class="rdage">Adult:</span> <span class="rdroute">IM</span> 50 U per site, may repeat in 4 mo<br/></td>
</tr>
</table>
<h1><a name="admintn">Administration</a></h1><span class="adminroutetype">Intramuscular, Intradermal, Subcutaneous</span><br/><ul>
<li>Slowly inject required amount of nonpreserved NS (see dilution calculation) into vial. Discard vial if a vacuum does not pull
            diluent into vial. Gently rotate to mix. Discard if not clear, colorless, and free of particulate matter. Dilution calculation:
            add 1, 2, 4, or 6 mL of NS to yield, respectively, 10 U/0.1 mL, 5 U/0.1 mL, 2.5 U/0.1 mL, 1.25 U/0.1 mL.
         </li>
<li>
            				Note: Injection intervals of BOTOX<sup>®</sup> Cosmetic should be at least 3 mo apart.
            			
         </li>
<li>Store at 2°8° C (refrigerated). Administer within 4 h of reconstitution.</li>
</ul>
<p><span class="routemethod">INCOMPATIBILITIES</span> Do not mix with other solutions/additives. 
      </p>
<h1><a name="adverse">Adverse Effects (<img src="../images/special/greaterorequal.gif"/>1%)</a></h1><span class="typehead"> Body as a Whole:</span> Injection site reactions (localized pain, tenderness, bruising), neck pain, flu-like symptoms, hypertonia, asthenia, fever. <span class="typehead"> CNS:</span>
<span class="speceff-common">Headache,</span> drowsiness. <span class="typehead"> GI:</span>
<span class="speceff-common"> Dysphagia,</span> dry mouth, fever, nausea, vomiting. <span class="typehead">Hematologic:</span> Ecchymosis. <span class="typehead">Musculoskeletal:</span> Local muscle weakness, dysarthria. <span class="typehead">Respiratory:</span> Cough, rhinitis, upper respiratory infection. <span class="typehead">Special Senses:</span>
<span class="speceff-common">Ptosis,</span> superficial punctate keratitis, dry eyes, ocular irritation, lacrimation, photophobia, keratitis, diplopia. 
      <h1><a name="interactions">Interactions</a></h1><span class="typehead">Drug:</span>
<span class="classification">aminoglycosides</span>, <span class="classification">neuromuscular blocking agents</span> may potentiate neuromuscular blockade; <b>chloroquine</b> may antagonize blocking effects. 
      <h1><a name="nursing"><span class="implictitle">Nursing Implications</span></a></h1>
<p><span class="adeffecttitle">Assessment &amp; Drug Effects</span></p>
<ul>
<li>Evaluate for therapeutic effectiveness, maximal at about 12 wk (lasting 34 mo).</li>
</ul>
<p><span class="eductitle">Patient &amp; Family Education</span></p>
<ul>
<li>Inform physician about all prescription, nonprescription, and herbal drugs being taken.</li>
<li>Report immediately any of the following: difficulty breathing or swallowing, problem with speech; unusual bleeding, bruising,
            or swelling around injection site.
         </li>
<li>
            							Note: Effects of the injection generally last 34 mo and then repeat treatments may be given.
            						
         </li>
<li>Do not breast feed without consulting physician.</li>
</ul>
<hr/>
<p><span class="footer">Common adverse effects in <i>italic</i>, life-threatening effects <u>underlined</u>; generic names in <b>bold</b>; classifications in <small>SMALL CAPS</small>; <img border="0" src="../images/maple.gif"/> Canadian drug name; <img border="0" src="../images/pr.gif"/> Prototype drug</span></p>
</body>